{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:07:21Z","timestamp":1753891641065,"version":"3.41.2"},"reference-count":35,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T00:00:00Z","timestamp":1745539200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:p>Headache is a significant public health issue due to its high prevalence, associated disability, and socioeconomic burden. In Japan, awareness of migraine prevention and the risks of medication overuse remains limited. This study examined whether increasing knowledge about headaches through an online educational campaign could lead to behavioral changes, such as more frequent visits to headache clinics and reduced misuse of headache medications. An online educational program on headaches was conducted for 1,829 hospital staff members, who first completed a questionnaire before watching an educational video. Six months later, they completed a second questionnaire to assess behavioral changes. The initial survey revealed that although headaches interfered with work and daily life for approximately 50% of participants, only 20% regularly sought medical care. The most common reason for not visiting a medical facility was reliance on over-the-counter medications. In the follow-up survey, 20% of participants had independently gathered information about headaches, 6% had visited a medical institution for a new headache, and 40% had reduced their use of painkillers after becoming aware of medication overuse headache (MOH). A decision tree model, using the reduction in painkiller use as the outcome, indicated that correct knowledge about migraine, including preventive treatments, and active information-seeking behavior were key factors in promoting behavioral change. These findings suggest that providing online headache education to hospital staff may contribute to improved headache management by increasing awareness of migraine prevention and MOH while reducing excessive painkiller use.<\/jats:p>","DOI":"10.3389\/fneur.2025.1572541","type":"journal-article","created":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T05:25:49Z","timestamp":1745558749000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Effectiveness of a headache awareness campaign on behavioral change"],"prefix":"10.3389","volume":"16","author":[{"given":"Shinsuke","family":"Muraoka","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takumi","family":"Asai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshihisa","family":"Nishizawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuki","family":"Nishida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Basile","family":"Chr\u00e9tien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryuta","family":"Saito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,4,25]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/S1474-4422(17)30299-5","article-title":"Global, regional, and national burden of neurological disorders during 1990\u20132015: a systematic analysis for the global burden of disease study 2015","volume":"16","year":"2017","journal-title":"Lancet Neurol"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1093\/med\/9780199584680.003.004","article-title":"Western Pacific region","volume-title":"Headache care, research and education worldwide","author":"Sakai","year":"2010"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1111\/j.1526-4610.2004.t01-4-04020.x","article-title":"Japanese with headache: suffering in silence","volume":"44","author":"Kotani","year":"2004","journal-title":"Headache"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1097\/01.jom.0000166864.58664.29","article-title":"The assessment of chronic health conditions on work performance, absence, and total economic impact for employers","volume":"47","author":"Collins","year":"2005","journal-title":"J Occup Environ Med"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1111\/j.1526-4610.2009.01369.x","article-title":"Economic burden of transformed migraine: results from the American migraine prevalence and prevention (AMPP) study","volume":"49","author":"Munakata","year":"2009","journal-title":"Headache"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s40259-022-00532-y","article-title":"Novel migraine therapies may reduce public and personal disadvantages for people with migraine","volume":"36","author":"Ambat","year":"2022","journal-title":"BioDrugs"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1080\/14712598.2022.2072207","article-title":"Treatment of migraine with monoclonal antibodies","volume":"22","author":"Serra L\u00f3pez-Matencio","year":"2022","journal-title":"Expert Opin Biol Ther"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1111\/head.14178","article-title":"Efficacy and safety of fremanezumab for episodic migraine prevention: multicenter, randomized, double-blind, placebo-controlled, parallel-group trial in Japanese and Korean patients","volume":"61","author":"Sakai","year":"2021","journal-title":"Headache"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s10194-021-01323-6","article-title":"CGRP antibody therapy in patients with drug resistant migraine and chronic daily headache: a real-world experience","volume":"22","author":"Scheffler","year":"2021","journal-title":"J Headache Pain"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1177\/0333102420949866","article-title":"Effect of calcitonin gene-related peptide (\u2212receptor) antibodies in chronic cluster headache: results from a retrospective case series support individual treatment attempts","volume":"40","author":"Ruscheweyh","year":"2020","journal-title":"Cephalalgia"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s40120-021-00305-9","article-title":"Burden of migraine in Japan: results of the ObserVational survey of the epidemiology, tReatment, and care of MigrainE (OVERCOME [Japan]) study [study]","volume":"11","author":"Matsumori","year":"2022","journal-title":"Neurol Ther"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"5176","DOI":"10.1007\/s12325-022-02289-w","article-title":"Potential unmet needs in acute treatment of migraine in Japan: results of the OVERCOME (Japan) study","volume":"39","author":"Takeshima","year":"2022","journal-title":"Adv Ther"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/0333102417738202","article-title":"The international classification of headache disorders, 3rd edition","volume":"38","year":"2018","journal-title":"Cephalalgia"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1177\/0333102417736898","article-title":"National awareness campaign to prevent medication-overuse headache in Denmark","volume":"38","author":"Carlsen","year":"2018","journal-title":"Cephalalgia"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1111\/head.12407","article-title":"Operational diagnostic criteria for chronic migraine: expert opinion","volume":"54","author":"Silberstein","year":"2014","journal-title":"Headache"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1111\/imj.14959","article-title":"The impact of an online adult headache guideline on headache referrals to the neurology clinic","volume":"51","author":"Huang","year":"2021","journal-title":"Intern Med J"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s10194-023-01700-3","article-title":"The World Health Organization Intersectoral global action plan on epilepsy and other neurological disorders and the headache revolution: from headache burden to a global action plan for headache disorders","volume":"25","author":"Leonardi","year":"2024","journal-title":"J Headache Pain"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/1129-2377-15-10","article-title":"Should we educate about the risks of medication overuse headache?","volume":"15","author":"Lai","year":"2014","journal-title":"J Headache Pain"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"3331024231165682","DOI":"10.1177\/03331024231165682","article-title":"Diagnosis, knowledge, perception, and productivity impact of headache education and clinical evaluation program in the workplace at an information technology company of more than 70,000 employees","volume":"43","author":"Sakai","year":"2023","journal-title":"Cephalalgia"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"100094","DOI":"10.1016\/j.ynpai.2022.100094","article-title":"Neurobiology of migraine progression","volume":"12","author":"Rattanawong","year":"2022","journal-title":"Neurobiol Pain"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1111\/j.1468-2982.2009.01941.x","article-title":"Global prevalence of chronic migraine: a systematic review","volume":"30","author":"Natoli","year":"2010","journal-title":"Cephalalgia"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1212\/WNL.0000000000003963","article-title":"Hypothalamus as a mediator of chronic migraine: evidence from high-resolution fMRI","volume":"88","author":"Schulte","year":"2017","journal-title":"Neurology"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1111\/j.1526-4610.2007.00853.x","article-title":"Brainstem dysfunction in chronic migraine as evidenced by neurophysiological and positron emission tomography studies","volume":"47","author":"Aurora","year":"2007","journal-title":"Headache"},{"volume-title":"Clinical Practice Guideline for Headache Disorders 2021","year":"2021","key":"ref24"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s10194-018-0951-2","article-title":"Preventive effects of galcanezumab in adult patients with episodic or chronic migraine are persistent: data from the phase 3, randomized, double-blind, placebo-controlled EVOLVE-1, EVOLVE-2, and REGAIN studies","volume":"19","author":"F\u00f6rderreuther","year":"2018","journal-title":"J Headache Pain"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s10194-020-01127-0","article-title":"A prospective real-world analysis of erenumab in refractory chronic migraine","volume":"21","author":"Lambru","year":"2020","journal-title":"J Headache Pain"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/s10194-022-01438-4","article-title":"Impact of fremanezumab on disability outcomes in patients with episodic and chronic migraine: a pooled analysis of phase 3 studies","volume":"23","author":"McAllister","year":"2022","journal-title":"J Headache Pain"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s10194-022-01396-x","article-title":"Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the FRIEND study)","volume":"23","author":"Barbanti","year":"2022","journal-title":"J Headache Pain"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s10194-021-01351-2","article-title":"Efficacy and safety of fremanezumab in clinical trial participants aged \u226560 years with episodic or chronic migraine: pooled results from 3 randomized, double-blind, placebo-controlled phase 3 studies","volume":"22","author":"Nahas","year":"2021","journal-title":"J Headache Pain"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1080\/03007995.2021.1971179","article-title":"Comprehensive population-based survey of migraine in Japan: results of the ObserVational survey of the epidemiology, tReatment, and care of MigrainE (OVERCOME [Japan]) study [study]","volume":"37","author":"Hirata","year":"2021","journal-title":"Curr Med Res Opin"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1111\/head.14153","article-title":"Board of Directors of the American headache society. The American headache society consensus statement: update on integrating new migraine treatments into clinical practice","volume":"61","author":"Ailani","year":"2021","journal-title":"Headache"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1111\/head.14721","article-title":"Characterizing gaps in the preventive pharmacologic treatment of migraine: multi-country results from the CaMEO-I study","volume":"64","author":"Buse","year":"2024","journal-title":"Headache"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1097\/00019052-200206000-00011","article-title":"Chronic daily headache: nosology and pathophysiology","volume":"15","author":"Welch","year":"2002","journal-title":"Curr Opin Neurol"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"3811","DOI":"10.1007\/s10072-021-05831-w","article-title":"Questionnaire-based survey on the prevalence of medication-overuse headache in Japanese one city-Itoigawa study","volume":"43","author":"Katsuki","year":"2022","journal-title":"Neurol Sci"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1111\/j.1468-2982.2007.01288.x","article-title":"The global burden of headache: a documentation of headache prevalence and disability worldwide","volume":"27","author":"Stovner","year":"2007","journal-title":"Cephalalgia"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2025.1572541\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T05:25:51Z","timestamp":1745558751000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2025.1572541\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,25]]},"references-count":35,"alternative-id":["10.3389\/fneur.2025.1572541"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2025.1572541","relation":{},"ISSN":["1664-2295"],"issn-type":[{"type":"electronic","value":"1664-2295"}],"subject":[],"published":{"date-parts":[[2025,4,25]]},"article-number":"1572541"}}